These issues, might arise at every step of the pharmaceutical value chain. Those who are making investments should be aware of common pitfalls so that they can structure their investments accordingly. They should also be familiar with international arbitration, the resolution mechanism of choice for these disputes.
In this roundtable, our partners and external expert will discuss:
- Structuring life sciences collaborations to minimise risk of disputes
- What to do before and after a dispute arises
- Why life sciences companies use international arbitration
- Strategies for investments in China
